If you searched "what is 5-Amino-1MQ" this year, you probably found a page that called it a peptide, explained that it "targets fat cells", and sold it to you a few paragraphs later. Two of those three things are wrong. 5-Amino-1MQ is not a peptide, and nobody has published a single study of what it does in a human being.
Here is the thesis, stated plainly. 5-Amino-1MQ is a small synthetic molecule whose entire evidence base is a handful of mouse studies from one university lab, and the scientists who created it have spent the years since developing a different compound. The consumer market did not wait for any of that. I think it is the cleanest case study we have of demand running ahead of evidence, and it is worth understanding exactly how that happens.
Nothing below is a suggestion to use, avoid or source this compound. It is a report on what is known, who is selling it, and why the gap between the two is so wide.
What is 5-Amino-1MQ, and is it actually a peptide?
The full name is 5-amino-1-methylquinolinium. It is a quinolinium salt, a small ring-shaped organic molecule with a molecular weight of roughly 159 daltons. A peptide is a chain of amino acids. BPC-157 is about 1,419 daltons; semaglutide is about 4,114. 5-Amino-1MQ is not a smaller peptide. It is a different kind of chemistry altogether, closer to a conventional pill drug than to anything in the peptide conversation.
It belongs to the peptide conversation anyway because of where it is sold. The same storefronts, clinic menus and YouTube explainers that carry BPC-157 and TB-500 carry 5-Amino-1MQ, often under a "peptides" tab. The label is a retail category, not a scientific one. That matters, because it lets a molecule borrow the credibility of a class it does not belong to.
Its target is an enzyme called nicotinamide N-methyltransferase, or NNMT. NNMT is highly expressed in fat tissue and uses up methyl groups and a precursor of NAD+ as it works. The hypothesis behind the research is that blocking NNMT in fat cells shifts their energy balance. It is a real and interesting hypothesis. It is also only a hypothesis in humans.
What does the research on 5-Amino-1MQ actually show?
The founding paper is Neelakantan and colleagues, published in Biochemical Pharmacology in 2018 by a group at the University of Texas Medical Branch in Galveston. They took mice made obese on a high-fat diet and treated them for 11 days, with nine animals per group.
The results were striking for a mouse study. Treated mice lost about 5% of body weight while controls gained about 1.4%. The epididymal fat pad shrank by roughly 35%, fat cells were more than 30% smaller in diameter, and plasma cholesterol was about 30% lower. Food intake did not change, which is the detail every sales page quotes, because it implies the compound works without appetite suppression.
A 2019 follow-up from the same group, again in Biochemical Pharmacology, looked at aged mice after muscle injury and reported about 70% greater peak torque in treated animals. Later papers from the same circle of researchers studied the gut microbiome and a combination with a reduced-calorie diet, all in mice.
That is the evidence base: eleven days in 18 obese mice, a muscle study in old mice, and a few mechanistic follow-ups, nearly all from one lab. The most underrated fact in this whole story is that small, short rodent studies of fat loss are among the least reliable predictors in metabolic research. Many compounds have shrunk mouse fat pads and done nothing useful in people.
Has 5-Amino-1MQ been tested in humans?
No, as far as the public record shows. There is no published human trial. A search of ClinicalTrials.gov on 24 September 2026 for 5-Amino-1MQ, for NNMT inhibitors and for the company developing the technology returned no registered study.
The company part is the revealing bit. The UTMB researchers licensed their NNMT inhibitor technology to a spin-out, Ridgeline Therapeutics, led by Stanley Watowich, one of the original authors. By March 2022 Ridgeline had raised more than $10 million in Department of Defense and NIH grants and was announcing a Phase 1 safety trial for late 2022. An NIH small-business profile later described a clinical candidate with first-in-human trials scheduled for the fourth quarter of 2023. Its first target was age-related muscle decline, not fat loss.
Two things follow. The clinical candidate described in those materials is a newer compound, not the 5-Amino-1MQ sold online. And the trial, if it happened, has not produced public results that we could find. So the people with the most knowledge of this molecule chose to take something else into humans, and the market chose to take the original straight to consumers.
Is 5-Amino-1MQ legal or FDA approved?
It is not FDA approved for anything. It is not on the 503A Bulks List, and it was not among the twelve peptides the FDA removed from its Category 2 list in April 2026. We found no FDA evaluation of it for compounding at all.
The FDA has, however, named it. In a warning letter dated 20 January 2026 to GenoGenix LLC, a 503B outsourcing facility in Boca Raton, Florida, the agency listed 5-Amino-1MQ and NAD+ as substances that "do not appear on the 503B bulks list" and are not used to compound a drug on the shortage list, which makes products compounded from them ineligible for the 503B exemptions. The same letter, based on an inspection in July 2025, described three patients who developed low blood pressure and uncontrollable shaking after an NAD+ product from that facility; testing found bacterial endotoxin at 3,360 EU/mL.
That letter is about one facility, and it does not settle the legal status of every product on the market. What it does show is that the FDA does not regard 5-Amino-1MQ as an eligible compounding ingredient for outsourcing facilities. As for the capsules sold as supplements, the sellers do not explain what legal basis they rely on, and the FDA has not, to our knowledge, ruled publicly on that question.
Who is selling 5-Amino-1MQ, and under what label?
Three channels, each with its own label. Research-chemical sites sell powder and vials marked "for research use only", a phrase that describes a legal posture rather than the actual buyer. Marketplaces including Amazon and eBay carry listings styled as supplements or as bulk powder with purity claims. And some clinics and telehealth services list it as a compounded prescription item, the channel the GenoGenix letter touched.
Look at the top results for the compound's name and you will find clinics, medspas, telehealth brands and vendors. Several of the pages that rank do admit, somewhere, that there is no human data, and several of those go on to publish a "protocol" anyway. The seller has written the explainer. That is the whole problem in one sentence.
Why is demand for 5-Amino-1MQ growing faster than the evidence?
I think four forces explain it. First, the mechanism is easy to narrate: an enzyme in fat cells, a switch, NAD+. A good story travels faster than a dataset. Second, it comes as a pill in most retail forms, which removes the needle and the psychological barrier that comes with it. Third, it rides in the slipstream of GLP-1 drugs, whose trials really did produce large, replicated weight loss in humans, and borrows their language without their data.
The fourth force is structural. The compound has no natural sponsor for a consumer-facing trial. The patent holders are developing a successor, and the sellers have every reason not to fund a study that could come back negative. When nobody is paid to find out, the question stays open, and an open question is the best marketing environment there is.
The fair objection: every drug starts in mice
The strongest counter-argument is that this is how all pharmacology begins. Semaglutide had mouse data once. Dismissing a compound because its evidence is preclinical would dismiss every drug before its Phase 1.
That is true, and the NNMT hypothesis may well turn out to be right. But the argument cuts the other way. Semaglutide went from mouse to market through tens of thousands of trial participants, dose-finding studies and safety monitoring. 5-Amino-1MQ skipped every one of those steps. The objection is a reason to take the research seriously. It is not a reason to treat eleven days in eighteen mice as if it were a label.
What the 5-Amino-1MQ story tells us
Strip away the storefronts and the picture is simple. A small molecule, not a peptide. One lab's mouse data. No published human trial. An FDA warning letter naming it as ineligible for outsourcing-facility compounding. A developer that moved on to a different compound. A retail market that grew anyway.
I expect we will see this pattern again with the next compound that has a clean mechanism and a mouse paper, and the defence is the same each time: ask who wrote the explainer and whether they are selling the product. We will keep tracking 5-Amino-1MQ and update this piece if human data or regulatory action appears. The monthly letter is where those updates land first.
Ozemback, September 2026